FDA Requires New GLP-1 Drug Warnings About a Potential Risk of Rare but Permanent Vision Loss

in people with type 2 diabetes who start GLP-1 RAs relative to those who begin DPP-4 or SGLT-2 inhibitor therapy. At the same time, interpreting adverse event reports in this area is difficult because many key NAION risk factors are already common in the populations that use GLP-1 RAs. Age over 50, diabetes itself, high blood pressure, smoking, sleep apnea, anemia, and kidney disease can all contribute to NAION risk. In the broader adult population older than 50, published data suggest NAION occurs in about 2.3 to 10.2

Leave a Reply

Your email address will not be published. Required fields are marked *